Sun Pharma and Samsung BioLogics have formed a strategic long-term manufacturing agreement for Tildrakizumab. The agreement was entered into by Sun Pharma’s wholly-owned subsidiary and Samsung BioLogics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. Filings for this novel investigational biologic has been accepted for review by the U.S. FDA (May 2017) and the European Medicines Agency (EMA) (March 2017). The agreement was signed at Samsung BioLogics’ headquarter in Incheon, South Korea. The approximate value of the contract will be $55.5 million.

“Samsung BioLogics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards,” said TH Kim, president and chief executive officer, Samsung BioLogics. “Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market.”

Kirti Ganorkar, global head, portfolio management and business development, Sun Pharma, said, “Samsung BioLogics is a globally renowned CMO. Through this partnership we will leverage Samsung’s manufacturing knowledge and world class quality systems to provide high quality products for the Tildrakizumab pipeline.”